Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 25 , ISSUE 12 ( December, 2021 ) > List of Articles

Original Article

Comparison of Clinical Characteristics and Outcome of Critically Ill Patients Admitted to Tertiary Care Intensive Care Units in India during the Peak Months of First and Second Waves of COVID-19 Pandemic: A Retrospective Analysis

Shanta Dutta, Aayushi Mahajan

Citation Information : Dutta S, Mahajan A. Comparison of Clinical Characteristics and Outcome of Critically Ill Patients Admitted to Tertiary Care Intensive Care Units in India during the Peak Months of First and Second Waves of COVID-19 Pandemic: A Retrospective Analysis. Indian J Crit Care Med 2021; 25 (12):1349-1356.

DOI: 10.5005/jp-journals-10071-24046

License: CC BY-NC 4.0

Published Online: 17-12-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Abstract

Background: Coronavirus disease-2019 (COVID-19) continues to pose serious challenges to healthcare systems globally with the disease progressing over time in crest-trough pattern of waves. We compared the patient characteristics and outcomes of critically ill patients admitted during the first and second waves of COVID-19 pandemic. Materials and Methods: We did a retrospective analysis of medical records of critically ill patients admitted to intensive care unit (ICU) at the peak period of both waves. The data on demographics, symptoms, treatment received, and outcomes of patients were recorded. Results: Compared to first wave, significantly more females, younger age group, and those without underlying comorbidities required ICU admission during the second wave. The treatments received during both periods were similar except for preferential use of methylprednisolone over dexamethasone and proclivity of bilevel positive airway pressure (BiPAP) ventilation over high-flow nasal cannula (HFNC). There was no significant difference in the duration of ICU stay and mortality of patients. During the first wave, the factors associated with nonsurvival of patients were advanced age, comorbidities, severe disease, and a lesser number of days on HFNC. All these factors along with higher Sequential Organ Failure Assessment (SOFA) score were observed to be linked with patient nonsurvival during the second wave. Conclusion: In India, the second wave of COVID-19 significantly influenced ICU demographics with a predominance of females and young adults requiring critical care. During both time periods, patients received similar treatment except for the propensity to use methylprednisolone and BiPAP as opposed to dexamethasone and HFNC in second wave. No significant difference in ICU mortality was noted.

HTML PDF Share
  1. Kumar S. Second wave of COVID-19: emergency situation in India. J Travel Med 2021;28(7):taab082. Available from: DOI: 10.1093/jtm/taab082.
  2. Jain VK, Iyenger KP, Vaishya R. Differences between first and second wave of COVID-19 in India. Diabetes Metab Syndr 2021;15(3):1047–1048. DOI: 10.1016/j.dsx.2021.05.009.
  3. Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M. Public health actions to control new SARS-CoV-2 variants. Cell 2021;184(5):1127–1132. DOI: 10.1016/j.cell.2021.01.044.
  4. Ramanathan M, Ferguson ID, Miao W, Khavari PA. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis 2021;21(8):1070. DOI: 10.1016/S1473-3 099(21)00262-0.
  5. Contou D, Fraisse M, Pajot O, Tirolien JA, Mentec H, Plantefeve G. Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave ? Crit Care 2021;25(1):3. DOI: 10.1186/s13054-020-03449-6.
  6. Karagiannidis C, Windisch W, McAuley D, Welte T, Busse R. Major differences in ICU admissions during first and second COVID-19 wave in Germany. Lancet Resp Med 2021;9(5):E47–E48. DOI: 10.1016/S2213-26 00(21)00101-6.
  7. Herold T, Jurinovic V, Amreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 2020;146(1):128–136.e4. DOI: 10.1016/j.jaci.2020.05.008.
  8. Kartz LM. (A little) Clarity on convalescent plasma for COVID-19. N Eng J Med 2021;384:666–668. DOI: 10.1056/NEJMe2035678.
  9. Government of India Ministry of Health and Family Welfare Director General of Health Services (EMR Division). Clinical management protocol: COVID-19; version 3.0. 2020. Available from: https://mohfw.gov.in.
  10. Government of India Ministry of Health and Family Welfare. Clinical management protocol: COVID-19; version 6.0. 2021. Available from: https://www.mohfw.gov.in/pdf/COVID19ClinicalManagementProtocolAlgorithmAdults19thMay2021.pdf.
  11. Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. The current second wave and COVID-19 vaccination status in India. Brain Behav Immun 2021;96:1–4. DOI: 10.1016/j.bbi.2021.05.018.
  12. Fisman DN, Tuite AR. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada. medRxiv 2021:2021.07.05.21260050. DOI: 10.1101/2021.07.05.21260050.
  13. Galasso V, Pons V, Profeta P, Becher M, Brouard S, Foucault M. Gender differences in COVID-19 attitudes and behavior: panel evidence from eight countries. Proc Natl Acad Sci USA 2020;117(44):27285–27291. DOI: 10.1073/pnas.2012520117.
  14. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Yonis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19.SN Compr Clin Med 2020;2:1069–1076.
  15. Guan W-J, Liang W-H, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55(5):2000547. DOI: 10.1183/13993003.00547-2020.
  16. Liang X, Shi Li, Wang Y, Xiao W, Duan G, Yang H, et al. The association of hypertension with severity and mortality COVID-19 patients: evidence based on adjusted effect estimates. J Infect 2020;81(3):e44–e47. DOI: 10.1016/j.jinf.2020.06.060.
  17. ZOE COVID Study. Available from: https://covid.joinzoe.com/post/new-top-5-covid-symptoms.
  18. Sudre CH, Keshet A, Graham MS, Joshi AD, Shilo S, Rossman H, et al. Anosmia, ageusia, and other COVID-19 like symptoms in association with a positive SARS-CoV-2 test across six national digital surveillance platforms: an observational study. Lancet Digit Health 2021;3(9):e577–e586. DOI: 10.1016/S2589-7500(21)00115-1.
  19. Von Bartheld CS, Hagen MM, Butowt R. The D614G virus mutation enhances anosmia in COVID-19 patients: evidence from asystematic review and meta-analysis of studies from south Asia. ACS Chem Neurosci 2021;12(9):3535–3549. DOI: 10.1021/acschemneuro.1c00542.
  20. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19-prelimnary report. N Engl J Med 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436.
  21. Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W, Qiao R. A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. J Intensive Care Med 2021;36(6):673–680. DOI: 10.1177/0885066621994057.
  22. Ranjbar K, Moghadami M, Mirahmadizadeh A. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 2021;21(1):337. DOI: 10.1186/s12879-021-06045-3.
  23. Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020;201(11):1430–1434. DOI: 10.1164/rccm.202003-07 36LE.
  24. Lim ZJ, Subramaniam A, Reddy MP, Blecher G, Kadam U, Afroz A, et al. Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. A meta-analysis. Am J Respir Crit Care Med 2021;203(1):54–66. DOI: 10.1164/rccm.202006-2405OC.
  25. Tobin MJ, Jubran A, Laghi F. Non-invasive strategies in COVID-19: epistemology, randomised trials, guidelines, physiology. Eur Respir J 2021;57(2):2004247. DOI: 10.1183/13993003.04247-2020.
  26. Doidge JC, Gould DW, Ferrando-Vivas P, Mouncey PR, Thomas K, Shankar-Hari M, et al. Trends in intensive care for patients with COVID-19 in England, Wales, and Northern Ireland. Am J Respir Crit Care Med 2021;203(5):565–574. DOI: 10.1164/rccm.202008-3212OC.
  27. Wang Z, Wang Y, Yang Z, Wu H, Liang J, Liang H, et al. The use of non-invasive ventilation in COVID-19: a systematic review. Int J Infect Dis 2021;106:254–261. DOI: 10.1016/j.ijid.2021.03.078.
  28. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J 2020;55(5):2000892. DOI: 10.1183/1399003.00892-2020.
  29. Mukhtar A, Lotfy A, Hasanin A, El-Hefnawy I, ElAdawy A. Outcome of non-invasive ventilation in COVID-19 critically ill patients: a retrospective observational study. Anaesth Crit Care Pain Med 2020;39(5):579–580. DOI: 10.1016/j.accpm.2020.07.012.
  30. Bellani G, Grasselli G, Cecconi M, AntoliniL, Borelli M, De Giacomi F, et al. Noninvasive ventilatory support of patients with COVID-19 outside the intensive care units (ward-COVID). Ann Am Thorac Soc 2021;18(6):1020–1026. DOI: 10.1513/AnnalsATS.202008-1080OC.
  31. Bravata DM, Perkins AJ, Meyers LJ, Arling G, Zhang Y, Zillich AJ, et al. Association of intensive care unit patient load and demand with mortality rates in US Department of Veterans Affair hospitals during the COVID-19 pandemic. JAMA Newt Open 2021;4(1):e2034266. DOI: 10.1001/jamanetworkopen2020.34266.
  32. Taccone FS, Goethem NV, Pauw R, Wittebole X, Blot K, Van Oyen H, et al. The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium. Lancet Regional Health-Europe 2020. DOI: 10.1016/j.lanepe.2020.100019.
  33. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.
  34. Thomson RJ, Hunter J, Dutton J, Schneider J, Khosravi M, Casement A, et al. Clinical characteristics and outcomes of critically ill patients with COVID-19 admitted to an intensive care unit in London: a prospective observational cohort study. PLoS One 2020;15(12):e0243710. DOI: 10.1371/journal.pone.0243710.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.